Orellana, Minerva
DSouza, Karen. N
Yap, Jane Q.
Sriganeshan, Abhirami
Jones, M. Elena
Johnson, Charis
Allyse, Megan
Venable, Sateria
Stewart, Elizabeth A.
Enders, Felicity
Balls-Berry, Joyce E.
Funding for this research was provided by:
National Center for Advancing Translational Sciences (TL1 TR002380, TL1 TR002380, UL1 TR002345)
Article History
Received: 24 December 2022
Accepted: 28 February 2024
First Online: 12 April 2024
Declarations
:
: All methods were carried out in accordance with relevant guidelines and regulations. The Mayo Clinic Institutional Review Board (IRB) acknowledges that based on the responses submitted for this new activity through the Mayo Clinic IRBe Human Subjects Research Wizard tool, and in accordance with the Code of Federal Regulations, 45 CFR 46.102, the above noted activity does not require IRB review for an IRB protocol. The Mayo Clinic IRB deemed the study exempt which means you do not have to do more than verbal consent which we obtained verbal informed consent at the start of our community engaged studios.
: Not applicable.
: The authors MO, KD, JQY, AS, MEJ, CJ, MA, FE, and JEBB report no competing interests. SV reports consulting for Abbvie, Pfizer, Myovant, and Bayer. EAS reports no competing interest directly related to this work. However, over the last 36 months she has received grant/research financial support from National Institutes for Health related to uterine fibroids (R01HD60503, R01HD109127-01A1, and P50HS023418); served as a consultant for AbbVie, Alnylam Pharmaceuticals, and Myovant; holds a patent for Methods and Compounds for Treatment of Abnormal Uterine Bleeding (US Patent 6440445), which has no commercial activity; and has received royalties from UpToDate and payments for the development of educational content from the Med Learning Group, MED-IQ, Omnia, Physicians Educational Resources, and Web-MD. She serves as an unpaid advisor to the Fibroid Foundation.